Luye Pharma’s Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for ...
Shanghai, July 4, 2024 — Luye Pharma Group announced that its Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) was approved for marketing by China's National Medical Products Administration (NMPA) on June 28, 2024, for the management of ...
July 04,2024
Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...
Shanghai, June 27, 2024 - Luye Pharma Group today announced that it has recently received an Establishment Inspection Report from the U.S. Food and Drug Administration (FDA) indicating that the manufacturing facility of Paliperidone Palmitate Extended-release Injectable Suspension ...
June 27,2024
20
2024-06
Luye Pharma’s Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
11
2024-06
Luye Pharma's Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
06
2024-06
NDA for Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia
29
2024-05
Boan’s Boluojia® (Denosumab) Approved for Marketing in China
29
2024-05
First in China: Biologics License Application for Boan Biotech’s Dulaglutide Injection Accepted
27
2024-03
Luye Pharma Announces 2023 Financial Results：Showing solid sales growth and improved financial structure
07
2024-03
Luye Pharma’s Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao
04
2024-03
First Patient Enrolled for Phase 3 Clinical Study of Luye Pharma’s Irinotecan Hydrochloride Liposome Injection (LY01610)
05
2024-02
Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea
13
2023-12
Luye Pharma’s Innovative Formulations Baituowei and Rykindo Included on China’s 2023 National Reimbursement Drug List
